Section
Diagnosis and management across the full skin-disease spectrum.
A JAAD study published October 17, 2026 finds week 4 abrocitinib response predicts week 12 remission in moderate-to-severe atopic dermatitis and correlates with glycolytic pathway modulation.
Dermatology Times' Social Media Mythbusters series tackles the viral claim that castor oil grows hair — a question clinicians now…
Bumpy brown torso patches in a woman cleared with an alcohol swab, revealing a novel form of terra firma-forme dermatosis and avo…
A young man's itchy netlike rash was traced to the ketogenic diet, with doctors reporting the same eruption after fasting — point…
Contemporary Pediatrics frames infant product selection around one criterion: protecting the immature skin barrier. Here's what t…
Medscape's latest clinical reminder urges clinicians to keep stasis dermatitis on the differential for lower-leg inflammation, wh…
A peer-reviewed paper on ScienceDirect reframes lactation accommodations in dermatology residency as an ethical obligation, not j…
A Nature study finds explainable AI for skin diagnosis affects clinicians and lay people differently — the same explanation can h…
Adults facing food insecurity report higher rates of eczema or skin allergy, a JAAD cross-sectional study of 2012 and 2024 NHIS d…
Dermatology patients in Gaza show what researchers call a crushing psychiatric burden, per a new report — skin disease and mental…
